ZJYL vs SYK

For growth investors, Jin Medical International Ltd.

(ZJYL) is the stronger pick with 18. 6% revenue growth year-over-year, versus 11. 2% for Stryker Corporation (SYK). Stryker Corporation (SYK) offers the better valuation at 35. 0x trailing P/E (19. 6x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Stryker Corporation (SYK) is the cheapest at 35.

0x versus Jin Medical International Ltd. at 93. 6x.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -72. 3% for Jin Medical International Ltd. (ZJYL). Over 10 years, the gap is even starker: SYK returned +187. 1% versus ZJYL's -72. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus Jin Medical International Ltd. 's 1. 57β — meaning ZJYL is approximately 187% more volatile than SYK relative to the S&P 500. On balance sheet safety, Jin Medical International Ltd. (ZJYL) carries a lower debt/equity ratio of 41% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Jin Medical International Ltd.

(ZJYL) is pulling ahead at 18. 6% versus 11. 2% for Stryker Corporation (SYK). On earnings-per-share growth, the picture is similar: Jin Medical International Ltd. grew EPS 18. 7% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Jin Medical International Ltd.

(ZJYL) is the more profitable company, earning 15. 6% net margin versus 12. 9% for Stryker Corporation — meaning it keeps 15. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus 15. 5% for ZJYL. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, SYK (1.

1% yield) pays a dividend. ZJYL does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Jin Medical International Ltd. (ZJYL) carries a higher beta of 1. 57 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +187. 1%, ZJYL: -72. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ZJYL is a small-cap high-growth stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while ZJYL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.